WO 2015/123734 Al 27 August 2015 (27.08.2015) P O P C T
Total Page:16
File Type:pdf, Size:1020Kb
(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2015/123734 Al 27 August 2015 (27.08.2015) P O P C T (51) International Patent Classification: (74) Agent: FB RICE; Level 23, 44 Market Street, Sydney, C08B 3/02 (2006.01) C07H 13/06 (2006.01) New South Wales 2000 (AU). C07H 13/04 (2006.0 1) A61K 9/14 (2006.0 1) (81) Designated States (unless otherwise indicated, for every (21) International Application Number: kind of national protection available): AE, AG, AL, AM, PCT/AU2015/050069 AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, (22) International Filing Date: DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, 23 February 2015 (23.02.2015) HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, (25) Filing Language: English KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, (26) Publication Language: English PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, (30) Priority Data: SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, 2014900566 2 1 February 2014 (21.02.2014) AU TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (71) Applicants: THE UNIVERSITY OF SYDNEY (84) Designated States (unless otherwise indicated, for every [AU/AU]; Sydney, Sydney, New South Wales 2006 (AU). kind of regional protection available): ARIPO (BW, GH, THE SYDNEY CHILDREN'S HOSPITAL NETWORK GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, (RANDWICK AND WESTMEAD) [AU/AU]; Cnr TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, Hawksbury Road & Hainsworth St, Westmead, New South TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, Wales 2145 (AU). DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, (72) Inventors: LITTLE, David Graham; 12 Glenridge Ave, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, West Pennant Hills, New South Wales 2125 (AU). GW, KM, ML, MR, NE, SN, TD, TG). CHENG, Tegan Laura; 159 Lawson Street, Redfern, New South Wales 2016 (AU). SCHINDELER, Aaron; 26/380 Published: Glenmore Parkway, Glenmore Park, New South Wales — with international search report (Art. 21(3)) 2745 (AU). DEHGHANI, Fariba; 154 Melwood Ave, Killarney Heights, New South Wales 2087 (AU). VALTCHEV, Peter; 27 Milner Ave, Hornsby, New South Wales 2077 (AU). (54) Title: LIQUID CARRIER MATERIALS 25 2 ! i ¾ S Figure 10 (57) Abstract: Abstract The invention relates to polymeric high viscosity liquid carrier materials (HVLCMs), in particular esterified polysaccharides, compositions comprising these HVLCMs, coatings for implants which are based on these HVLCMs, methods of their production and their use in delivering substances, including drugs and bioactive agents, systemically to a body as a sustained release device, or locally, as employed in bone tissue engineering and other applications. Liquid Carrier Materials Cross-Reference to Related Application The present application claims priority from Australian Provisional Patent Application 2014900566 filed on 2 1 February 2014, the content of which is incorporated herein by reference. Technical Field The disclosure relates to polymeric high viscosity liquid carrier materials (HVLCMs), their method of production and use in delivering substances, including drugs and bioactive agents, systemically to a body as a sustained release device, or locally, as employed in bone tissue engineering and other applications. Background of the Invention Biomaterials engineering is an emerging biomedical field that involves the design and manufacture of new systems for delivering bioactive agents to various parts of the body. In bone tissue engineering the main class of bioactive agents currently used are the recombinant human bone morphogenetic proteins (rhBMPs), which are capable of inducing the formation of large amounts of new bone. Historically, the primary approach has been to deliver rhBMPs in porous solid scaffolds. Disadvantages with this method include a requirement for surgical implantation and a general inefficiency in the production of new bone. Some delivery systems can be delivered via injection. The majority of current generation injectable materials are hydrogels. Chitosan/ -glycerophosphate, hyaluronic acid and PEG/fibrinogen hydrogels have shown a capacity to deliver rhBMP-2. Materials such as these hydrogels have several significant limitations. A critical constraint is the requirement for an implantable containment device or scaffold to prevent unwanted dispersal of the delivery system in vivo. Alternative injectable systems can be phase transitioned by UV curing, but this method again requires surgery and presents an infection risk. Injectable poly( -hydroxy acid) polymers and foaming polymers have been developed, but bulk degradation with large polymer implants can create an acidic microenvironment that impairs osteoconduction. Micro-and nanoparticle encapsulation are also methods for injectable systems. Ceramics which phase transition from liquid to solid have also been utilised for delivery. However, while some promising experimental results have been put forward, these have not proven effective for tissue engineering and bone repair, and are not currently available. Alternative delivery systems involve the use of non-polymeric high viscosity liquid carrier materials (HVLCM), such as sucrose acetate isobutyrate (SAIB). SAIB is a monomeric sugar-based ester of sucrose and acetic and isobutyric acids. It is highly viscous and demonstrates properties of a semi-solid material. SAIB is an injectable medium that has been used as a carrier for specific bioactive agents including systemic pharmaceuticals, local anaesthetics and delivering actives to promote bone repair in vivo. SAIB advantageously is able to stay at the site where it is administered and provides a reduced risk of infection associated with open implantation. However, its application is somewhat limited by its hydrophobicity which can retard solubility of actives and promote precipitation and denaturing of some actives. There is a need for new carrier and delivery systems that are able to deliver a range of substances and are diverse in their application to a patient or subject. Any discussion of documents, acts, materials, devices, articles or the like which has been included in the present specification is not to be taken as an admission that any or all of these matters form part of the prior art base or were common general knowledge in the field relevant to the present disclosure as it existed before the priority date of each claim of this application. Summary of the Invention Polymeric high viscosity liquid carrier materials (HVLCMs) have been developed and disclosed herein as alternative delivery systems for delivering agents including pharmaceutical drugs and bioactive agents. The HVLCMs disclosed herein are suitable for delivering substances locally or systemically. In a first aspect, the invention provides an esterified polysaccharide which is a homopolymer or copolymer comprising esterified sugar monomer units, wherein the sugar monomer units are esterified ketose or aldose sugars. In a second aspect, the invention provides an esterified polysaccharide which is a homopolymer or copolymer comprising esterified sugar monomer units, where the sugar monomer units are selected from: esterified 2-deoxyribose, esterified 2-deoxy-D- ribose, esterified fructose, esterified galactose, esterified glucose, esterified 2-deoxy- glucose, esterified 2-deoxy-D-glucose, esterified arabinose, esterified lyxose, esterified, esterified ribose, esterified xylose, esterified ribulose, esterified xyulose, esterified allose, esterified altrose, esterified mannose, esterified gulose esterified, esterified idose, esterified talose, esterified psicose, esterified fructose, esterified sorbose, esterified tagatose, or a mixture thereof. In a third aspect, the invention provides an esterified polysaccharide which is a homopolymer comprising esterified sugar monomer units, wherein the sugar monomer units are esterified 2-deoxyribose monomer units. In a fourth aspect, the invention provides an esterified polysaccharide which is a homopolymer comprising esterified sugar monomer units, wherein the sugar monomer units are esterified fructose monomer units. In a fifth aspect, the invention provides an esterified polysaccharide which is a homopolymer comprising esterified sugar monomer units, wherein the sugar monomer units are esterified galactose monomer units. In a sixth aspect, the invention provides an esterified polysaccharide which is a homopolymer comprising esterified sugar monomer units, wherein the sugar monomer units are esterified glucose monomer units. In a seventh aspect, the invention provides a pharmaceutical composition comprising the esterified polysaccharide according to any one of the first to sixth aspects, together with one or more pharmaceutically acceptable carriers and/or excipients. In an eighth aspect, the invention provides a method to promote bone growth, the method comprising providing a composition according to the seventh aspect to a site in a subject to promote bone growth at the site. In a ninth aspect, the invention provides a method to heal wounds in or on a subject, the method comprising a step of providing a composition according to the seventh aspect, to a wound site in or on the subject to promote healing of the wound. In